Hutson

1652
#10

Errors Corrected by the STIC Systems Branch

Serial Number: 09/117,380B

ENTERED

- ☐ Changed a file from non-ASCII to ASCII
- ☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.
- ☐ Edited a format error in the Current Application Data section, specifically: _____
- ☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other _____.
- ☐ Added the mandatory heading and subheadings for "Current Application Data".
- ☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.
- ☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically: _____
- ☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were: _____
- ☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited: _____
- ☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.
- ☐ Inserted colons after headings/subheadings. Headings edited included: _____
- ☐ Deleted extra, invalid, headings used by an applicant, specifically: _____
- ☑ Deleted: ☑ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as _____.
- ☐ Inserted mandatory headings, specifically: _____
- ☐ Corrected an obvious error in the response, specifically: _____
- ☐ Edited identifiers where upper case is used but lower case is required, or vice versa.
- ☐ Corrected an error in the Number of Sequences field, specifically: _____
- ☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.
- ☐ Deleted *ending* stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____
- ☐ Other: _____

RECEIVED
AUG 02 1999
TECH CTR

***Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.**

3/1/95

1652

RAW SEQUENCE LISTING DATE: 07/25/2000
PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

<110> APPLICANT: FRIDKIN, Matityahu
YAVIN, Eran J.
<120> TITLE OF INVENTION: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN
<130> FILE REFERENCE: FRIDKIN=1
<140> CURRENT APPLICATION NUMBER: 09/117,380B
<141> CURRENT FILING DATE: 1999-01-27
<150> PRIOR APPLICATION NUMBER: PCT/IL97/00032
<151> PRIOR FILING DATE: 1997-01-27
<150> PRIOR APPLICATION NUMBER: IL 116976
<151> PRIOR FILING DATE: 1996-01-31
<160> NUMBER OF SEQ ID NOS: 20
<170> SOFTWARE: PatentIn Ver. 2.0
<210> SEQ ID NO: 1
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<220> FEATURE:
<223> OTHER INFORMATION: The N-terminal Ala residue is modified with a methoxysuccinyl group; the C-terminal Val residue is modified with a nitroanilide group.
<400> SEQUENCE: 1
Ala Ala Pro Val
1
<210> SEQ ID NO: 2
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: The N-terminal Ala residue is modified with a succinyl group; the C-terminal Phe residue is modified with a nitroanilide group.
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 2
Ala Ala Pro Phe
1
<210> SEQ ID NO: 3
<211> LENGTH: 206
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<223> OTHER INFORMATION: The C-terminal Pro residue is modified with an OH group.
<400> SEQUENCE: 3
Glu Thr Asp Met Ser Arg Lys Ala Phe Val Phe Pro Lys Glu Ser Asp

RAW SEQUENCE LISTING DATE: 07/25/2000
PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

```
70   1               5                  10                  15
72 Thr Ser Tyr Val Ser Leu Lys Ala Pro Leu Thr Lys Pro Leu Lys Ala
73              20                  25                  30
75 Phe Thr Val Cys Leu His Phe Tyr Thr Glu Leu Ser Ser Thr Arg Gly
76          35                  40                  45
78 Tyr Ser Ile Phe Ser Tyr Ala Thr Lys Arg Gln Asp Asn Glu Ile Leu
79      50                  55                  60
81 Ile Phe Trp Ser Lys Asp Ile Gly Tyr Ser Phe Thr Val Gly Gly Ser
82  65                  70                  75                  80
84 Glu Ile Leu Phe Glu Val Pro Glu Val Thr Val Ala Pro Val His Ile
85                  85                  90                  95
87 Cys Thr Ser Trp Glu Ser Ala Ser Gly Ile Val Glu Phe Trp Val Asp
88              100                 105                 110
90 Gly Lys Pro Arg Val Arg Lys Ser Leu Lys Lys Gly Tyr Thr Val Gly
91          115                 120                 125
93 Ala Glu Ala Ser Ile Ile Leu Gly Gln Glu Gln Asp Ser Phe Gly Gly
94      130                 135                 140
96 Asn Phe Glu Gly Ser Gln Ser Leu Val Gly Asp Ile Gly Asn Val Asn
97 145                 150                 155                 160
99 Met Trp Asp Phe Val Leu Ser Pro Asp Glu Ile Asn Thr Ile Tyr Leu
100                 165                 170                 175
102 Gly Gly Pro Phe Ser Pro Asn Val Leu Asn Trp Arg Ala Leu Lys Tyr
103             180                 185                 190
105 Glu Val Gln Gly Glu Val Phe Thr Lys Pro Gln Leu Trp Pro
106         195                 200                 205
109 <210> SEQ ID NO: 4
110 <211> LENGTH: 28
111 <212> TYPE: PRT
112 <213> ORGANISM: Homo sapiens
114 <220> FEATURE:
115 <221> NAME/KEY: DISULFID
116 <222> LOCATION: (24)..(25)
118 <400> SEQUENCE: 4
119 Ser Phe Thr Val Gly Gly Ser Glu Ile Leu Phe Glu Val Pro Glu Val
120   1               5                  10                  15
122 Thr Val Ala Pro Val His Ile Cys Cys Leu His Phe
123             20                  25
126 <210> SEQ ID NO: 5
127 <211> LENGTH: 28
128 <212> TYPE: PRT
129 <213> ORGANISM: Artificial Sequence
131 <220> FEATURE:
132 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
134 <400> SEQUENCE: 5
135 Thr Ile Asn Glu Lys Gly Thr Glu Ala Ala Gly Ala Met Phe Leu Glu
136   1               5                  10                  15
138 Ala Ile Pro Met Thr Ile Pro Pro Glu Val Lys Phe
139             20                  25
142 <210> SEQ ID NO: 6
```

RAW SEQUENCE LISTING DATE: 07/25/2000
PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<220> FEATURE:
<221> NAME/KEY: DISULFID
<222> LOCATION: (9)..(10)
<400> SEQUENCE: 6
Val Thr Val Ala Pro Val His Ile Cys Cys Leu His Phe
1 5 10

<210> SEQ ID NO: 7
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 7
Gly Ser Glu Ile Leu Phe Glu Val Pro Glu Val Thr Val Ala Pro Val
1 5 10 15
His Ile Cys Cys His Leu Phe
20

<210> SEQ ID NO: 8
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 8
Val Thr Val Ala Pro Val Ser Ile
1 5

<210> SEQ ID NO: 9
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 9
Val Thr Val Ala Pro Val Phe Ile
1 5

<210> SEQ ID NO: 10
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<220> FEATURE:
<223> OTHER INFORMATION: The C-terminal Pro residue is modified with an NH2 group

RAW SEQUENCE LISTING DATE: 07/25/2000
PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

213 <400> SEQUENCE: 10
214 Val Thr Val Ala Pro Val His Ile Pro
215 1 5
218 <210> SEQ ID NO: 11
219 <211> LENGTH: 9
220 <212> TYPE: PRT
221 <213> ORGANISM: Artificial Sequence
223 <220> FEATURE:
224 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
226 <220> FEATURE:
227 <223> OTHER INFORMATION: The C-terminal Pro residue is modified with an
228 NH2 group
230 <400> SEQUENCE: 11
231 Val Thr Val Ala Pro Phe His Ile Pro
232 1 5
235 <210> SEQ ID NO: 12
236 <211> LENGTH: 10
237 <212> TYPE: PRT
238 <213> ORGANISM: Artificial Sequence
240 <220> FEATURE:
241 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
243 <220> FEATURE:
244 <223> OTHER INFORMATION: The C-terminal Pro residue is modified with an NH2
245 group
247 <400> SEQUENCE: 12
248 Val Thr Val Ala Pro Val His Ile Pro Pro
249 1 5 10
252 <210> SEQ ID NO: 13
253 <211> LENGTH: 8
254 <212> TYPE: PRT
255 <213> ORGANISM: Artificial Sequence
257 <220> FEATURE:
258 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
260 <220> FEATURE:
261 <223> OTHER INFORMATION: The N-terminal Val residue may be modified with a
262 monomethoxy-succinyl group, a 1,adamantyl-NH-CO
263 group, an a-naphtyl-NH-CO group, an octanoyl group, a
264 carbobenzoxy protecting group, a 6-actylamino-N-hexanoyl
W--> 265 group, a 9-fluorenylmethoxycarbonly group, an H-group, a
W--> 266 CH3OCO(CH2)2CO group, a CH3(CH2)6CO group, or a CH3CONH(CH2)5CO
W--> 267 group.
W--> 269 The C-terminal Ile residue may be modified with an OH group
W--> 270 or an NH2 group,
272 <400> SEQUENCE: 13
273 Val Thr Val Ala Pro Val His Ile
274 1 5
277 <210> SEQ ID NO: 14
278 <211> LENGTH: 9
279 <212> TYPE: PRT

RAW SEQUENCE LISTING DATE: 07/25/2000
PATENT APPLICATION: US/09/117,380B TIME: 13:16:53

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

```
     280 <213> ORGANISM: Artificial Sequence
     282 <220> FEATURE:
     283 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     285 <220> FEATURE:
     286 <223> OTHER INFORMATION: The N-terminal Phe residue may be modified with a
     287       monomethoxy-succinyl group, a carbobenzoxy
     288       protecting group, a CH3OCO(CH2)2C) group, or an H group
     291       The C-terminal Ile residue may be modified with an OH
W--> 292       group or joined to a polymer
     296 <400> SEQUENCE: 14
     297 Phe Val Thr Val Ala Pro Val His Ile
     298   1               5
     301 <210> SEQ ID NO: 15
     302 <211> LENGTH: 8
     303 <212> TYPE: PRT
     304 <213> ORGANISM: Artificial Sequence
     306 <220> FEATURE:
     307 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     309 <400> SEQUENCE: 15
     310 Leu Glu Ala Ile Pro Met Ser Ile
     311   1               5
     314 <210> SEQ ID NO: 16
     315 <211> LENGTH: 8
     316 <212> TYPE: PRT
     317 <213> ORGANISM: Artificial Sequence
     319 <220> FEATURE:
     320 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     322 <220> FEATURE:
     323 <223> OTHER INFORMATION: Xaa at position 7 is 1,4-(L)diaminobutyric acid
     325 <400> SEQUENCE: 16
W--> 326 Val Thr Val Ala Pro Val Xaa Ile
     327   1               5
     330 <210> SEQ ID NO: 17
     331 <211> LENGTH: 8
     332 <212> TYPE: PRT
     333 <213> ORGANISM: Artificial Sequence
     335 <220> FEATURE:
     336 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     338 <220> FEATURE:
     339 <223> OTHER INFORMATION: Xaa at position 5 is N-methyl glycine
     341 <400> SEQUENCE: 17
W--> 342 Val Thr Val Ala Xaa Val His Ile
     343   1               5
     346 <210> SEQ ID NO: 18
     347 <211> LENGTH: 9
     348 <212> TYPE: PRT
     349 <213> ORGANISM: Artificial Sequence
     351 <220> FEATURE:
     352 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
```

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/117,380B

DATE: 07/25/2000
TIME: 13:16:54

Input Set : A:\Pto.amc
Output Set: N:\CRF3\07252000\I117380B.raw

L:265 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:266 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:267 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:269 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:270 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:292 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:326 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:16
L:326 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:16
L:326 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:16
L:342 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:17
L:342 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:17
L:342 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:17
L:398 M:259 W: Field exceeds allowed number of lines, <223> Other Information:

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/117,380B

DATE: 05/05/2000
TIME: 12:16:14

Input Set : A:\fridkin1.txt
Output Set: N:\CRF3\05052000\I117380.raw

Does Not Comply
Corrected Diskette Needed

```
  3 <110> APPLICANT: FRIDKIN, Matityahu
  4       YAVIN, Eran J.
  6 <120> TITLE OF INVENTION: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE
  7       PROTEIN
  9 <130> FILE REFERENCE: FRIDKIN=1
 11 <140> CURRENT APPLICATION NUMBER: 09/117,380
 12 <141> CURRENT FILING DATE: 1999-01-27
 14 <150> PRIOR APPLICATION NUMBER: PCT/IL97/00032
 15 <151> PRIOR FILING DATE: 1997-01-27
 17 <150> PRIOR APPLICATION NUMBER: IL 116976
 18 <151> PRIOR FILING DATE: 1996-01-31
 20 <160> NUMBER OF SEQ ID NOS: 20
 22 <170> SOFTWARE: PatentIn Ver. 2.0
```

ERRORED SEQUENCES

```
385 <210> SEQ ID NO: 20
386 <211> LENGTH: 8
387 <212> TYPE: PRT
388 <213> ORGANISM: Artificial Sequence
390 <220> FEATURE:
391 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
393 <220> FEATURE:
394 <223> OTHER INFORMATION: The N-terminal Val residue is modified with an H
395       group; Thr at position 2 is modified with
396       tert.-butyl-ether; His at position 7 is modified
397       with trityl; and the C-terminal Ile residue is joined to a
W--> 398       polymer
400 <400> SEQUENCE: 20
401 Val Thr Val Ala Pro Val His Ile
402   1               5
E--> 408 1
```

VERIFICATION SUMMARY DATE: 05/05/2000
PATENT APPLICATION: US/09/117,380B TIME: 12:16:15

Input Set : A:\fridkin1.txt
Output Set: N:\CRF3\05052000\I117380.raw

L:265 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:266 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:267 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:269 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:270 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:292 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:326 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:16
L:326 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:16
L:326 M:340 W: (46) "n" or "Xaa" used: Feature required, for SEQ ID#:16
L:342 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:17
L:342 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:17
L:342 M:340 W: (46) "n" or "Xaa" used: Feature-required, for SEQ ID#:17
L:398 M:259 W: Field exceeds allowed number of lines, <223> Other Information:
L:408 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:20